NCT07071844
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07071844
Title BETWEEN: Biweekly Bevacizumab + Trifluridine/Tipiracil to Reduce Grade 3-4 Neutropenia in mCRC Patients (BETWEEN)
Acronym BETWEEN
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors GERCOR - Multidisciplinary Oncology Cooperative Group
Indications
Therapies
Age Groups: senior | adult
Covered Countries FRA


No variant requirements are available.